Maravirov MAI-III(Acid impurity)

Maravirov MAI-III (Acid impurity) is a degradation byproduct of the antiretroviral drug Maraviroc, characterized by a pyrazole-fused cyclopropyl core with a terminal carboxylic acid group. Its structure retains the 1,2,4-triazole scaffold but lacks the N-ethyl substitution at the piperidine ring of the parent compound, introducing a polar acidic moiety. This impurity arises via hydrolytic cleavage of the Maraviroc ester linkage under acidic conditions. It serves as a critical HPLC reference standard for quantifying process-related impurities in Maraviroc formulations.